<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05050981</url>
  </required_header>
  <id_info>
    <org_study_id>40147320.5.0000.0082</org_study_id>
    <nct_id>NCT05050981</nct_id>
  </id_info>
  <brief_title>Effects of Menopause Hormonal Therapy and Selective Serotonin Reuptake Inhibitor on Cognition, Sexual Function and Quality of Life</brief_title>
  <official_title>Comparison of Effects of Menopause Hormonal Therapy and Selective Serotonin Reuptake in Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Faculdade de Medicina do ABC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Faculdade de Medicina do ABC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cross-sectional study with postmenopausal women using hormone therapy or serotonin reuptake&#xD;
      inhibitor to relieve climacteric symptoms or without any treatment. Participants will answer&#xD;
      three questionnaires: FSFI (the Female Sexual Function Index), MENQOL (Menopause-specific&#xD;
      Quality of Life) and MEEM (Mini-Mental State Examination). The results will be compared&#xD;
      according to treatment group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Climacteric is a period marked by the reduction of estrogen levels, which leads to the&#xD;
      occurrence of various symptoms that can affect a woman's physical, mental, sexual health and&#xD;
      quality of life. The use of hormonal therapy (HT), with replacement of estrogen or estrogen&#xD;
      and progestin, is indicated to alleviate these symptoms, aiming to improve the woman's&#xD;
      quality of life. In addition, it is possible to use other forms of treatment to alleviate&#xD;
      these symptoms, including selective serotonin reuptake inhibitors (SSRI), which play a major&#xD;
      role in vasomotor symptoms. SSRIs have been used with moderate success in women who have&#xD;
      contraindications to the use of HT or do not wish to use it. Objective: This study aims to&#xD;
      analyze and compare the effects of HT and SSRIs in the treatment of climacteric symptoms in&#xD;
      relation to cognitive and sexual function and quality of life in climacteric women.&#xD;
      Methodology: This is a cross-sectional study to be carried out with 120 climacteric patients&#xD;
      treated at the Centro de Atenção Integral à Saúde da Mulher (CAISM) in the city of São&#xD;
      Bernardo do Campo/SP/Brazil. Participants who sign the Informed Consent Form will answer 3&#xD;
      questionnaires: FSFI (Female Sexual Function Index), WHOQOL-Bref (World Health Organization&#xD;
      Quality of Life Instrument Bref) and MEEM (Mini-Mental State Examination). The results will&#xD;
      be compared according to treatment group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Score at Female Sexual Function Index scale (DSDI)</measure>
    <time_frame>Day 1</time_frame>
    <description>Association between treatments and FSFI global score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Score at World Health Organization quality of life assessment - bref scale (WHOQOL-Bref)</measure>
    <time_frame>Day 1</time_frame>
    <description>Association between treatments and WHOQOL-Bref score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Score at Mini-Mental State Examination scale</measure>
    <time_frame>Day 1</time_frame>
    <description>Association between treatments and Mini-Mental State Examination score</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Menopause</condition>
  <arm_group>
    <arm_group_label>HT</arm_group_label>
    <description>Women using hormone replacement therapy (estrogen only or oestrogen and progestin) for treating climacteric symptoms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SSRI</arm_group_label>
    <description>Women using selective serotonin reuptake inhibitors for treating climacteric symptoms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Women not using hormone replacement therapy or selective serotonin reuptake inhibitors</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hormone replacement therapy</intervention_name>
    <description>Hormone replacement therapy: menopause hormone therapy with estrogen-only or oestrogen-progestin.</description>
    <arm_group_label>HT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selective serotonin reuptake inhibitors</intervention_name>
    <description>Selective serotonin reuptake inhibitors: anyone in the category, e.g.: fluoxetine, sertraline, etc.</description>
    <arm_group_label>SSRI</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Postmenopausal women aged between 45 and 65 years who are literate treated with hormone&#xD;
        replacement therapy or selective serotonin reuptake inhibitors for relieve of cllimacteric&#xD;
        symptoms, or not yet under any of both treatment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Postmenopausal women aged between 45 and 65 years who are literate;&#xD;
&#xD;
          -  Patients with at least 6 months of follow-up at the institution and who consented to&#xD;
             participate in the research.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with psychiatric illness;&#xD;
&#xD;
          -  Being on medication with action on the Central Nervous System due to psychiatric&#xD;
             indication;&#xD;
&#xD;
          -  Cognitive impairment that makes it impossible to understand the issues;&#xD;
&#xD;
          -  Illiteracy;&#xD;
&#xD;
          -  Absence of at least one sexual activity in the last 4 weeks.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Luciano M Pompei</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculdade de Medicina do ABC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luciano M Pompei</last_name>
    <phone>+551149937227</phone>
    <email>luciano.pompei@fmabc.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centro de Atenção Integral à Saúde da Mulher</name>
      <address>
        <city>São Bernardo do Campo</city>
        <state>SP</state>
        <zip>09760-280</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luciano M Pompei</last_name>
      <phone>+55 11 4335-3214</phone>
      <email>luciano.pompei@fmabc.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 2, 2021</study_first_submitted>
  <study_first_submitted_qc>September 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2021</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Faculdade de Medicina do ABC</investigator_affiliation>
    <investigator_full_name>Luciano de Melo Pompei'</investigator_full_name>
    <investigator_title>Auxiliary Professor at Gynecology Department</investigator_title>
  </responsible_party>
  <keyword>menopause</keyword>
  <keyword>hormone replacement therapy</keyword>
  <keyword>selective serotonin reuptake inhibitors</keyword>
  <keyword>sexual function</keyword>
  <keyword>quality of life</keyword>
  <keyword>cognition</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Serotonin</mesh_term>
    <mesh_term>Serotonin Uptake Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>This is a small study to know regional data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

